



# Marksans Pharma Ltd.

November 17, 2025

**BSE Limited**

Corporate Relation Department  
Phiroze Jeejeebhoy Towers,  
Dalal Street,  
Mumbai - 400001.

**Scrip Code: 524404**

**National Stock Exchange of India Limited**

Listing Department  
Exchange Plaza, C-1, Block-G,  
Bandra-Kurla Complex,  
Bandra (East), Mumbai - 400051.

**Symbol: MARKSANS**

**Sub: Newspaper advertisement of financial results for the quarter and half year ended September 30, 2025**

Dear Sir/Madam,

Pursuant to Regulation 47 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, kindly find enclosed herewith copies of newspaper advertisement pertaining to Unaudited Financial Results of the Company for the quarter and half year ended September 30, 2025 published on November 15, 2025 in the Business Standard (English) and Lakshadeep (Marathi) newspapers.

We request you to take the aforesaid on records.

Thanking You.

Yours faithfully,

For **Marksans Pharma Limited**

**Harshavardhan Panigrahi**  
**Company Secretary**

Encl: As above

**Marksans Pharma Ltd.**

11th Floor, "GRANDEUR", Opp. Gundecha Symphony, Veera Desai Extension Road, Oshiwara,  
Andheri (W), Mumbai - 400 053 • Tel.: +91 22 4001 2000 • E-mail: info@marksanspharma.com

www.marksanspharma.com



## J.G. Chemicals Limited

Advantz Infinity@5, Unit No. 1511, Street No. 18, BN Block,  
Sector - V, Salt Lake City, Kolkata - 700 091, India,  
Email: corporate@jgchem.com | Web: www.jgchem.com  
CIN: L24100WB2001PLC093380

### Statement of Unaudited Consolidated Financial Results for the Quarter and Six Months ended 30th September 2025

(₹ in Crores except EPS data)

Particulars	Quarter ended			Half year ended		Year ended
	30-09-2025 (Unaudited)	30-06-2025 (Unaudited)	30-09-2024 (Unaudited)	30-09-2025 (Unaudited)	30-09-2024 (Unaudited)	31-03-2025 (Audited)
Revenue from operations	220.27	218.01	212.08	438.29	414.61	847.94
Net Profit / (Loss) for the period (before tax and exceptional items)	20.35	21.85	23.15	42.20	44.39	89.90
Net Profit / (Loss) for the period before tax (after exceptional items)	20.35	21.85	23.15	42.20	44.39	89.90
Net Profit / (Loss) for the period after tax	15.03	16.36	17.14	31.39	33.05	66.76
Total comprehensive income for the period	15.03	18.60	23.30	33.62	39.20	69.11
Paid up Equity Share Capital [Face value ₹10 per share]	39.19	39.19	39.19	39.19	39.19	39.19
Total Reserves	-	-	-	-	-	425.57
Earnings per Equity Share (of ₹ 10 each) -Basic and Diluted (Not Annualised*)	*3.67	*4.03	*4.21	*7.70	*8.09	16.34

#### Notes:

1. Additional information on Unaudited Standalone Financial Results is as follows: (₹ in Crores)

Particulars	Quarter ended			Half year ended		Year ended
	30-09-2025 (Unaudited)	30-06-2025 (Unaudited)	30-09-2024 (Unaudited)	30-09-2025 (Unaudited)	30-09-2024 (Unaudited)	31-03-2025 (Audited)
Revenue from operations	59.60	70.97	70.94	130.56	135.95	271.82
Profit before exceptional item and tax	5.53	8.47	8.52	14.00	13.63	27.00
Profit before tax	5.53	8.47	8.52	14.00	13.63	27.00
Profit after tax	4.14	6.37	6.29	10.51	10.12	20.02

2. The Unaudited Consolidated Financial Results and Unaudited Standalone Financial Results have been reviewed by the Audit Committee and approved by the Board of Directors at its meeting held on 14th November, 2025. The Statutory Auditors have given Limited Review Report on these results.

3. The above is an extract of the detailed format of Financial Results filed with Stock Exchanges under Regulation 33 of SEBI (LODR) Regulations, 2015. The full format of the standalone and consolidated Financial Results for the quarter ended September 30, 2025 are available on the BSE Limited website (URL: www.bseindia.com), the National Stock Exchange of India Limited website (URL: www.nseindia.com) and on the Company's website (URL: www.jgchem.com).

4. These results have been prepared in accordance with the Indian Accounting Standards (referred to as "Ind AS") Financial Reporting prescribed under Section 133 of the Companies Act, 2013 read with Companies (Indian Accounting Standards) Rules as amended from time to time.



By order of the Board  
For J.G. Chemicals Limited  
Sd/-  
Suresh Jhunjhunwala  
Chairman and Whole-time Director

Date : 14.11.2025  
Place: Kolkata

## BASF India Limited

Regd. Office : Unit No.10A, 10B & 10C (part), 10<sup>th</sup> Floor, Godrej One, Pirojsha Nagar,  
Eastern Express Highway, Vikhroli (East), Mumbai - 400 079, India.  
Tel: 022-69347000.



### EXTRACT OF CONSOLIDATED UNAUDITED FINANCIAL RESULTS FOR THE QUARTER AND SIX MONTHS ENDED SEPTEMBER 30, 2025

Rs. in million

Particulars	Quarter Ended		Six Months Ended		Year Ended
	30/09/2025 (Unaudited)	30/09/2024 (Unaudited)	30/09/2025 (Unaudited)	30/09/2024 (Unaudited)	31/03/2025 (Audited)
Revenue from operations	40,453.3	42,477.2	79,198.7	82,146.2	152,600.0
Net Profit/ (Loss) for the period (before tax, before exceptional items)	1,435.0	1,711.9	3,311.7	4,540.5	6,167.7
Exceptional items	-	-	-	137.8	292.9
Net Profit for the period (before tax, after exceptional items)	1,435.0	1,711.9	3,311.7	4,678.3	6,460.6
Net Profit for the period (after tax, after exceptional items)	1,071.5	1,279.3	2,445.5	3,485.0	4,790.6
Total Comprehensive Income for the period (Comprising Profit/(Loss) for the period (after tax) and Other Comprehensive Income (after tax))	1,096.3	1,304.8	2,409.2	3,507.7	4,787.4
Equity Share Capital (Face value of Rs 10/- each)	432.9	432.9	432.9	432.9	432.9
Reserves (excluding Revaluation Reserves) as shown in the Balance Sheet of previous year	-	-	-	-	35,909.9
Earnings Per Share (EPS):					
Basic and diluted EPS after exceptional items (not annualised) (Face value of Rs 10/- each)	24.8	29.6	56.5	80.5	110.7
Basic and diluted EPS before exceptional items (not annualised) (Face value of Rs 10/- each)	24.8	29.6	56.5	78.1	105.6

### EXTRACT OF STANDALONE UNAUDITED FINANCIAL RESULTS FOR THE QUARTER AND SIX MONTHS ENDED SEPTEMBER 30, 2025

Rs. in million

Particulars	Quarter Ended		Six Months Ended		Year Ended
	30/09/2025 (Unaudited)	30/09/2024 (Unaudited)	30/09/2025 (Unaudited)	30/09/2024 (Unaudited)	31/03/2025 (Audited)
Revenue from operations	39,040.4	42,477.2	76,558.2	82,146.2	151,623.5
Net Profit/ (Loss) for the period (before tax, before exceptional items)	1,355.9	1,712.0	3,361.4	4,540.7	6,333.9
Exceptional items	-	-	-	137.8	365.3
Net Profit for the period (before tax, after exceptional items)	1,355.9	1,712.0	3,361.4	4,678.5	6,699.2
Net Profit for the period (after tax, after exceptional items)	1,010.5	1,279.4	2,482.0	3,485.2	4,992.0
Total Comprehensive Income for the period (Comprising Profit/(Loss) for the period (after tax) and Other Comprehensive Income (after tax))	1,029.2	1,304.9	2,442.1	3,507.9	4,989.5
Equity Share Capital (Face value of Rs 10/- each)	432.9	432.9	432.9	432.9	432.9
Reserves (excluding Revaluation Reserves) as shown in the Balance Sheet of previous year	-	-	-	-	36,138.2
Earnings Per Share (EPS):					
Basic and diluted EPS after exceptional items (not annualised) (Face value of Rs 10/- each)	23.3	29.6	57.3	80.5	115.3
Basic and diluted EPS before exceptional items (not annualised) (Face value of Rs 10/- each)	23.3	29.6	57.3	78.1	109.0

#### Notes:

1. The above is an extract of the detailed format of Quarterly/ Annual Financial Results filed with the Stock Exchanges under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The full format of the Quarterly/ Annual Financial Results are available on the Stock Exchange websites viz., www.bseindia.com and www.nseindia.com and can be also accessed by scanning the QR code provided below.

2. The above statement of consolidated and standalone unaudited financial results for BASF India Limited for the quarter and six months ended September 30, 2025 have been reviewed by the Audit Committee and approved by the Board of Directors at its meeting held on November 14, 2025. The above results have been subjected to limited review by the Statutory Auditors.



On behalf of the Board of Directors  
Alexander Gerding  
Managing Director  
DIN : 09797186

CIN No.: L33112MH1943FLC003972  
Mumbai  
November 14, 2025



Regd. Office: 37, First Floor, Kamala Bhavan II, S. Nityanand Road, Andheri (East), Mumbai - 400 069,  
Tel: 022 - 6726 1000, Fax No.: 022 - 6726 1068, E-mail: - corporaterelations@guficbio.com, website: www.gufic.com

### STATEMENT OF UNAUDITED STANDALONE AND CONSOLIDATED FINANCIAL RESULTS OF THE COMPANY FOR THE QUARTER AND HALF YEAR ENDED SEPTEMBER 30, 2025

The Unaudited Standalone and Consolidated Financial Results for the quarter and half year ended September 30, 2025 have been reviewed by the Audit Committee and approved by the Board of Directors of the Company at their respective meetings held on Friday, November 14, 2025.

The said Financial Results along with the Limited Review Report, are available on the website of the Company at <https://gufic.com/media/investors/quarterly-reports/> and on the website of the Stock Exchanges namely BSE Limited at [www.bseindia.com](http://www.bseindia.com) and National Stock Exchange of India Limited at [www.nseindia.com](http://www.nseindia.com) where shares of the Company are listed and can be accessed by scanning the below QR code:



Date: November 14, 2025  
Place: Mumbai

By order of the Board of Directors  
For Gufic Biosciences Limited

Sd/-  
Pranav Choksi  
Chief Executive Officer and Whole Time Director  
(DIN: 0001731)

Note: The above intimation is in accordance with Regulation 33 read with Regulation 47(1) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.



## MARKSANS PHARMA LIMITED

Registered Office: 11<sup>th</sup> Floor, Grandeur, Veera Desai Extension Road, Oshiwara, Andheri [West], Mumbai - 400053.  
Telephone No.: 022-4001 2000, Fax No.: 022-4001 2011, E-mail: companysecretary@marksanspharma.com

### STATEMENT OF UNAUDITED FINANCIAL RESULTS FOR THE QUARTER AND HALF YEAR ENDED SEPTEMBER 30 2025

(₹ in million except per equity share data)

Sr. No.	PARTICULARS	STANDALONE			CONSOLIDATED		
		QUARTER ENDED	HALF YEAR ENDED	QUARTER ENDED	QUARTER ENDED	HALF YEAR ENDED	QUARTER ENDED
		30 Sept 2025 (UNAUDITED)	30 Sept 2025 (UNAUDITED)	30 Sept 2024 (UNAUDITED)	30 Sept 2025 (UNAUDITED)	30 Sept 2025 (UNAUDITED)	30 Sept 2024 (UNAUDITED)
1	Total Income from operations	3,786.30	7,003.74	3,288.52	7,419.81	13,676.11	6,418.52
2	Net Profit / (Loss) for the period before Tax	1,214.93	1,850.67	763.37	1,333.34	2,099.32	1,245.97
3	Net Profit / (Loss) for the period after Tax	998.06	1,478.62	632.04	991.39	1,573.41	977.60
4	Total Comprehensive Income for the period [Comprising Profit/(Loss) for the period (after tax) and Other Comprehensive Income (after tax)]	997.32	1,477.12	632.74	1,356.06	2,603.37	1,543.64
5	Paid up Equity Share Capital (face value ₹1 each fully paid)	453.16	453.16	453.16	453.16	453.16	453.16
6	Earnings per equity share of ₹1 each*						
	- Basic	2.20	3.26	1.39	2.17	3.45	2.13
	- Diluted	2.20	3.26	1.39	2.17	3.45	2.13

\* EPS is not annualised for the quarter and half year ended 30 September 2025, and quarter ended 30 September 2024.

Note : The above is an extract of the detailed format of Unaudited Financial Results for the quarter and half year ended 30 September 2025 filed with the Stock Exchanges under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The full format of the Unaudited Financial Results are available on www.nseindia.com and www.bseindia.com and Company's website www.marksanspharma.com.



Date : 13 November 2025

www.marksanspharma.com

For MARKSANS PHARMA LIMITED

MARK SALDANHA  
Chairman & Managing Director  
DIN : 00020983

The shareholders who have not registered their e-mail addresses are requested to register them with the Company to receive e-communication from the Company. For registering e-mail address, the shareholders are requested to follow the below steps:  
i. Shareholders holding shares in physical mode are requested to provide name, folio number, mobile number, e-mail address, scanned copies of self attested share certificate(s) (both sides) copy of PAN/ Aadhaar through e-mail on [companysecretary@marksanspharma.com](mailto:companysecretary@marksanspharma.com) or alternatively, do the same through the Registrar and Transfer Agent's website link at: <https://www.bigshareonline.com/investorRegistration.aspx>.  
ii. Shareholders holding shares in dematerialised mode are requested to register their email addresses and mobile numbers with their relevant depositories through their depository participants.

## KRIDHAN INFRA LIMITED

Corporate Identification Number (CIN): L27100MH2006PLC160602  
Registered Office: 203, Joshi Chambers, Ahmedabad Street, Carnac Bunder, Masjid (East), Mumbai 400009, Maharashtra, India  
Tel No: 96196 66510 E-mail: cs@kridhan.com Website: www.kridhan.com

### Extract of Unaudited Standalone and Consolidated Financial Results for the quarter and half year ended 30th September 2025

Sr. No.	Particulars	STANDALONE					CONSOLIDATED						
		Quarter Ended		Half Year Ended		Year Ended	Quarter Ended		Half Year Ended		Year Ended		
		30/09/2025 (Unaudited)	30/09/2024 (Unaudited)	30/09/2025 (Unaudited)	30/09/2024 (Unaudited)	31/03/2025 (Audited)	30/09/2025 (Unaudited)	30/09/2024 (Unaudited)	30/09/2025 (Unaudited)	30/09/2024 (Unaudited)	31/03/2025 (Audited)		
1	Total Income from Operations	125.00	154.25	-	279.25	-	257.67	125.00	154.25	-	279.25	-	257.67
2	Net Profit / (Loss) for the period (before Tax, Exceptional and/or Extraordinary items)	27.20	31.51	(25.42)	58.71	(30.25)	24.48	25.81	31.99	(26.50)	57.42	(31.31)	19.05
3	Net Profit / (Loss) for the period before tax (after Exceptional and/or Extraordinary items)	27.16	123.06	6,726.97	150.26	6,722.14	7,231.81	25.81	123.14	6,728.71	148.95	6,723.90	7,229.20
4	Net Profit / (Loss) for the period after tax (after Exceptional and/or Extraordinary items) including profit/loss from associate	27.20	123.06	6,726.97	150.26	6,722.14	7,231.81	25.81	123.14	6,728.71	148.95	6,723.90	7,229.20
5	Total Comprehensive Income for the period [Comprising Profit / (Loss) for the period (after tax) and Other Comprehensive Income (after tax) including profit/loss from associate	27.20	123.06	6,726.97	150.26	6,722.14	7,231.81	25.81	123.14	6,728.71	148.95	6,723.90	7,229.20
6	Equity Share Capital	1,895.58	1,895.58	1,895.58	1,895.58	1,895.58	1,895.58	1,895.58	1,895.58	1,895.58	1,895.58	1,895.58	1,895.58
7	No. of Shares	947.79	947.79	947.79	947.79	947.79	947.79	947.79	947.79	947.79	947.79	947.79	947.79
8	Earnings Per Share (of Rs. 2/- each) (for continuing and discontinued operations)												
	1. Basic & Diluted	0.03	0.13	7.10	0.16	7.08	7.83	0.03	0.13	7.10	0.16	7.09	7.83

#### Notes:

1. The above financial results have been reviewed by the Audit Committee and approved by the Board of Directors at its meetings held on 14th November, 2025 without Limited Review Report in terms of Regulations 33 of SEBI (Listing and Other Disclosure Requirements) Regulations, 2015. A casual vacancy in the position of the Statutory Auditors of the Company was arise due to sudden sad demise of M/s. B.R. Kolesha & Co., Chartered Accountants, a statutory auditor of the Company. The Company has today appointed M/s. Jignesh Savta & Associates, Chartered Accountants as a statutory auditor of the Company to fill the said casual vacancy of the Statutory Auditors of the Company. The Company will publish the financial results for the quarter and half year ended September 30, 2025 along with limited review report from new Statutory Auditor, M/s. Jignesh Savta & Associates, Chartered Accountants in due course of time.

2. As informed earlier, the subsidiary Company at Singapore viz. ReadyMade Steel Singapore Pte. Ltd. is under liquidation process and hence due to non-availability of its financial information, the same have not been considered in the above consolidated financial results. The Company in its standalone financials has already impaired its investments and loans outstanding in the said subsidiary. In view of the same, there will be no material impact of the said liquidation on the financials of the Company.

3. The Company operates in a single business segment but there are two geographical segments. However since the figures for Singapore subsidiaries are not available as mentioned above, the segment reporting is not submitted.

4. Since the Company has already impaired its investments and loans outstanding in the said Associate Company viz. Vijay Nirman Company Private Limited, in its consolidated financials, there is no impact in the current consolidated financials and hence not considered in the results.

5. Exceptional items are on account of Reversals of earlier provisions for Loans & Advances.

6. The Company has accumulated losses incurred in the past years which have resulted in erosion of Company's Net Worth. The future Business prospects along with Cost reduction measures will support the company's Continued Operations and enable it to continue as a going concern. Accordingly, the financial results are prepared on going concern basis. The recent efforts taken by the company to increase its equity base by way of preferential allotment of equity / warrants will support the growth of business activities.

7. The above is an extract of the detailed format of Financial Results filed with the Stock Exchanges under Regulation 33 of the SEBI (Listing and Other Disclosure Requirements) Regulations, 2015. The full format of the Financial Results are available on the Stock Exchange website [www.bseindia.com](http://www.bseindia.com) and [www.nseindia.com](http://www.nseindia.com) and our Company's website [www.kridhan.com](http://www.kridhan.com).

8. Previous periods' figures have been rearranged / regrouped wherever considered necessary to conform to the presentation of the current period.

For and on behalf of Board of Directors

Sd/  
Gautam Suri  
Managing Director  
DIN No.: 08180233

Place: Mumbai  
Date: 14/11/2025

